Passage BIO (PASG) Net Equity Issued and Repurchased (2019 - 2024)
Passage BIO (PASG) posted quarterly Net Equity Issued and Repurchased of $8.7 million for Q1 2024, up 874100.0% quarter-over-quarter from $1000.0 in Q4 2021.
Passage BIO (PASG) Net Equity Issued and Repurchased (2019 - 2024) Analysis & Trends
Passage BIO's Net Equity Issued and Repurchased history runs 4 years deep, the most recent figure standing at $8.7 million for Q1 2024.
- In Q1 2024, Net Equity Issued and Repurchased changed N/A year-over-year to $8.7 million; the TTM figure through Dec 2024 stood at $8.7 million (changed N/A YoY), while the FY2024 annual figure was $8.7 million, changed N/A from the prior year.
- Net Equity Issued and Repurchased for Q1 2024 stood at $8.7 million, up from $1000.0 in the prior quarter.
- The five-year high for Net Equity Issued and Repurchased was $229.9 million in Q1 2020, with the low at -$1.6 million in Q2 2020.
- The 3-year median for Net Equity Issued and Repurchased is $8.7 million (2024), against an average of $80.6 million.
- Peak annual rise in Net Equity Issued and Repurchased reached 1050.61% in 2020, while the deepest fall reached 106.24% in 2020.
- Passage BIO's Net Equity Issued and Repurchased stood at -$1.6 million in 2020, then soared by 100.06% to $1000.0 in 2021, then surged by 874100.0% to $8.7 million in 2024.
- Business Quant data shows PASG's Net Equity Issued and Repurchased at $8.7 million in Q1 2024, $1000.0 in Q4 2021, and $165.8 million in Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Passage BIO | 13.99 Mn | 13.99 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 8.74 Mn |
| Mar 31, 2024 | 8.74 Mn |
| Dec 31, 2021 | 1,000.00 |
| Dec 31, 2021 | 1,000.00 |
| Mar 31, 2021 | 165.81 Mn |
| Mar 31, 2021 | 165.81 Mn |
| Jun 30, 2020 | -1.64 Mn |
| Jun 30, 2020 | -1.64 Mn |
| Mar 31, 2020 | 229.90 Mn |
| Mar 31, 2020 | 229.90 Mn |
| Jun 30, 2019 | 26.33 Mn |
| Jun 30, 2019 | 26.33 Mn |
| Mar 31, 2019 | 19.98 Mn |
| Mar 31, 2019 | 19.98 Mn |